Document Detail

Pharmacogenomics and adverse drug reactions: the case of statins.
MedLine Citation:
PMID:  21568825     Owner:  NLM     Status:  MEDLINE    
INTRODUCTION: The use of genomics to predict adverse drug reactions (ADRs) has been the subject of much research over the last decade. Concerns about the muscular safety of statins, a highly prescribed group of drugs, are partially related to their high exposure. Many studies have identified a variety of genetic markers related to statin-induced myopathy. However, only polymorphisms in the SLCO1B1 gene (which encodes the carrier responsible for the hepatic uptake of statins, which, in turn, contributes to the regulation of plasma levels of SLCO1B1) were strongly associated with statin-induced muscular adverse effects. These was found to be most prominent for simvastatin. The strength of these findings relies on the use of modern genetic approaches, such as well-designed, case-controlled and genome-wide association studies. Nevertheless, the clinical use of this information is far from known at present and needs to be evaluated.
AREAS COVERED: The links between genetic polymorphisms (i.e., SLCO1B1 gene) and statin-induced muscle ADRs and the methodological issues involved in the establishment of such an association are explored.
EXPERT OPINION: Despite there being a statin-gene association for myopathy, in the case of some statins the usefulness of this information still needs to be proven.
Mariano A Giorgi; Christian Caroli; Hernán Cohen Arazi; Guillermo Di Girolamo
Related Documents :
24739305 - Popgenome: an efficient swiss army knife for population genomic analyses in r.
10564585 - Analysis of ptch/smo/shh pathway genes in medulloblastoma.
16890805 - Targeting loss-of-function mutations in tumor-suppressor genes as a strategy for develo...
25350605 - Combining magnetic sorting of mother cells and fluctuation tests to analyze genome inst...
22410825 - Thermographic evaluation of climatic conditions on lambs from different genetic groups.
18218765 - Quantitative trait loci affecting milk yield and protein percentage in a three-country ...
Publication Detail:
Type:  Journal Article; Review     Date:  2011-03-29
Journal Detail:
Title:  Expert opinion on pharmacotherapy     Volume:  12     ISSN:  1744-7666     ISO Abbreviation:  Expert Opin Pharmacother     Publication Date:  2011 Jul 
Date Detail:
Created Date:  2011-06-09     Completed Date:  2011-09-28     Revised Date:  2013-11-06    
Medline Journal Info:
Nlm Unique ID:  100897346     Medline TA:  Expert Opin Pharmacother     Country:  England    
Other Details:
Languages:  eng     Pagination:  1499-509     Citation Subset:  IM    
Copyright Information:
© 2011 Informa UK, Ltd.
Department of Cardiology and Cardiovascular Surgery, Montañeses 2325 (1428), FLENI, Buenos Aires, Argentina.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Genetic Markers
Genome-Wide Association Study
Hydroxymethylglutaryl-CoA Reductase Inhibitors / adverse effects*,  pharmacokinetics
Liver / metabolism
Muscular Diseases / chemically induced*,  genetics
Organic Anion Transporters / blood,  genetics
Polymorphism, Genetic
Simvastatin / adverse effects
Reg. No./Substance:
0/Genetic Markers; 0/Hydroxymethylglutaryl-CoA Reductase Inhibitors; 0/Organic Anion Transporters; 0/SLCO1B1 protein, human; 79902-63-9/Simvastatin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Sensory acceptability of iron-fortified millet products.
Next Document:  Mitochondrial quality control and dynamics in Parkinson's disease.